Samuel Lentz to Endometrial Neoplasms
This is a "connection" page, showing publications Samuel Lentz has written about Endometrial Neoplasms.
Connection Strength
0.445
-
Lentz SS. Endometrial carcinoma diagnosed by positron emission tomography: a case report. Gynecol Oncol. 2002 Aug; 86(2):223-4.
Score: 0.215
-
Whitney CW, Brunetto VL, Zaino RJ, Lentz SS, Sorosky J, Armstrong DK, Lee RB. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004 Jan; 92(1):4-9.
Score: 0.059
-
Gallion HH, Brunetto VL, Cibull M, Lentz SS, Reid G, Soper JT, Burger RA, Andersen W. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2003 Oct 15; 21(20):3808-13.
Score: 0.058
-
Covens A, Brunetto VL, Markman M, Orr JW, Lentz SS, Benda J. Phase II trial of danazol in advanced, recurrent, or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2003 Jun; 89(3):470-4.
Score: 0.057
-
Miller DS, Blessing JA, Lentz SS, Waggoner SE. A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2002 Dec; 87(3):247-51.
Score: 0.055